U.K. House of Commons committee demands more clinical-trial transparency

09/18/2013 | PharmaTimes (U.K.)

A House of Commons Science and Technology Committee report says too many clinical trials remain unregistered and unpublished, and the lack of transparency undermines public trust, slows medical progress and potentially puts patients at risk. The committee does not advocate uncontrolled release of patient-level data, but does urge stronger government action to facilitate sharing of raw clinical-trial data.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA